N-(butylaminocarbonyl)-2-oxyindole | 64460-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(butylaminocarbonyl)-2-oxyindole
• 英文别名: 2-oxo-2,3-dihydro-indole-1-carboxylic acid butylamide；N-butyl-2-oxo-3H-indole-1-carboxamide
• CAS: 64460-91-9
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: KKRYIAJBVSMRMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG
  申请人：Okayama University

  公开号：EP2910547B1

  公开（公告）日：2017-06-14
• USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES
  申请人：Boehringer Ingelheim Pharma KG

  公开号：EP1530466A2

  公开（公告）日：2005-05-18
• US9512075B2
  申请人：——

  公开号：US9512075B2

  公开（公告）日：2016-12-06
• [EN] USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES<br/>[FR] UTILISATION D'INHIBITEUR LCK POUR LE TRAITEMENT D'AFFECTIONS IMMUNOLOGIQUES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004017948A2

  公开（公告）日：2004-03-04

  The invention relates to a method of treating immunologc diseases or pathological conditions involving an immunologc component using Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressive, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said LcK inhibitoir together with said other drugs, and the use of LcK inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.